Skip to content
Screener

Arrowhead Research ARWR EV / EBITDA

EV / EBITDA at other companies

ALN
Alnylam PharmaceuticalsALNY
36.7×—
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
5.5×—
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

enterprise value/ebitda=27.4×

Based on the most recent quarter.

The source filing: Arrowhead Research’s 10-Q, filed February 5, 2026. Open the filing →

Filed
Feb 5, 2026, 4:06 PM EST
Fiscal quarter
Q1 FY2026
Calendar quarter
Q4 2025
Accession
0000879407-26-000034

FAQ

What is Arrowhead Research's EV / EBITDA?
Arrowhead Research (ARWR) reported EV / EBITDA of 27.4× in Q4 2025.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Arrowhead Research's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude